HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shock index and prediction of traumatic hemorrhagic shock 28-day mortality: data from the DCLHb resuscitation clinical trials.

AbstractINTRODUCTION:
To assess the ability of the shock index (SI) to predict 28-day mortality in traumatic hemorrhagic shock patients treated in the diaspirin cross-linked hemoglobin (DCLHb) resuscitation clinical trials.
METHODS:
We used data from two parallel DCLHb traumatic hemorrhagic shock efficacy trials, one in U.S. emergency departments, and one in the European Union prehospital setting to assess the relationship between SI values and 28-day mortality.
RESULTS:
In the 219 patients, the mean age was 37 years, 64% sustained a blunt injury, 48% received DCLHb, 36% died, and 88% had an SI≥1.0 at study entry. The percentage of patients with an SI≥1.0 dropped by 57% (88 to 38%) from the time of study entry to 120 minutes after study resuscitation (p<0.001). Patients with a SI≥1.0, 1.4, and 1.8 at any time point were 2.3, 2.7, and 3.1 times, respectively, more likely to die by 28 days than were patients with SI values below these cutoffs (p<0.001). Similarly, after 120 minutes of resuscitation, patients with a SI≥1.0 were 3.9× times more likely to die by 28 days (40 vs. 15%, p<0.001). Although the distribution of SI values differed based on treatment group, the receiver operator characeristics data showed no difference in SI predictive ability for 28-day mortality in patients treated with DCLHb.
CONCLUSION:
In these traumatic hemorrhagic shock patients, the shock index correlates with 28-day mortality, with higher SI values indicating greater mortality risk. Although DCLHb treatment did alter the distribution of SI values, it did not influence the ability of the SI to predict 28-day mortality.
AuthorsEdward P Sloan, Max Koenigsberg, James M Clark, William B Weir, Nora Philbin
JournalThe western journal of emergency medicine (West J Emerg Med) Vol. 15 Issue 7 Pg. 795-802 (Nov 2014) ISSN: 1936-9018 [Electronic] United States
PMID25493120 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Substitutes
  • Hemoglobins
  • diaspirin-cross-linked hemoglobin
  • Aspirin
Topics
  • Adult
  • Aspirin (analogs & derivatives, therapeutic use)
  • Blood Substitutes (therapeutic use)
  • Emergency Medical Services
  • Europe (epidemiology)
  • Female
  • Fluid Therapy
  • Hemoglobins (therapeutic use)
  • Humans
  • Male
  • Predictive Value of Tests
  • Resuscitation (methods, mortality)
  • Shock, Hemorrhagic (etiology, mortality, prevention & control, therapy)
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • United States (epidemiology)
  • Wounds and Injuries (complications, mortality, physiopathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: